Demo
LUCD Nasdaq· Lucid Diagnostics Inc
FundamentalsNews digest Peer analysis
Login
LUCD Nasdaq· Lucid Diagnostics Inc
Earnings report Q3 2023

Lucid Diagnostics Inc. Reports Significant Increase in Revenue in Latest Quarter

Segments of revenue

In the latest quarter, Lucid Diagnostics Inc. reported revenue of $783,000, compared to $76,000 in the same quarter of the previous year. This represents a substantial increase of $707,000 or 930%. The increase in revenue can be attributed to the revenue generated from Lucid's own CLIA laboratory operations, particularly from the EsoGuard Esophageal DNA Test.

Strengths

Lucid Diagnostics Inc. demonstrated strong financial performance in the latest quarter, with a significant increase in revenue. The company's transition to its own laboratory operations has allowed it to generate higher revenue from its EsoGuard Esophageal DNA Test. Lucid's management highlighted the successful transition and the positive impact it had on the company's financial results.

Challenges

Despite the increase in revenue, Lucid Diagnostics Inc. reported an operating loss of $11.1 million in the latest quarter. This loss can be attributed to the high operating expenses incurred by the company, including costs of revenue, sales and marketing, general and administrative expenses, amortization of acquired intangible assets, and research and development expenses. Lucid will need to carefully manage its expenses to improve its profitability.

Noteworthy

Lucid Diagnostics Inc. terminated its Commercialization Agreement with RDx in the previous year and transitioned to its own laboratory operations. This strategic move allowed the company to generate higher revenue from its EsoGuard Esophageal DNA Test. Additionally, Lucid implemented a new revenue cycle management provider, resulting in improved claims processing and appeals, leading to faster collections and increased percentage of claims paid.

Summary

Lucid Diagnostics Inc. reported a significant increase in revenue in the latest quarter, driven by the revenue generated from its own CLIA laboratory operations. The company's transition to its own laboratory operations and the termination of the Commercialization Agreement with RDx have positively impacted its financial performance. However, Lucid also reported an operating loss due to high operating expenses. Overall, Lucid Diagnostics Inc. showed promising growth in revenue but needs to address its operating expenses to improve profitability.

Source documents

Form 10-Q  filed on Nov 13, 2023
7 pages scanned

Reference data

Company financials Q3 revenue 783k
Analyst estimates Q3 EPS missed by -1.49%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.